NO20014046D0 - Gabapentinderivater for forhindring og behandling av visceral smerte - Google Patents

Gabapentinderivater for forhindring og behandling av visceral smerte

Info

Publication number
NO20014046D0
NO20014046D0 NO20014046A NO20014046A NO20014046D0 NO 20014046 D0 NO20014046 D0 NO 20014046D0 NO 20014046 A NO20014046 A NO 20014046A NO 20014046 A NO20014046 A NO 20014046A NO 20014046 D0 NO20014046 D0 NO 20014046D0
Authority
NO
Norway
Prior art keywords
prevention
treatment
visceral pain
gabapentin derivatives
gabapentin
Prior art date
Application number
NO20014046A
Other languages
English (en)
Other versions
NO20014046L (no
Inventor
Justin Stephen Bryans
Laurent Diop
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20014046D0 publication Critical patent/NO20014046D0/no
Publication of NO20014046L publication Critical patent/NO20014046L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20014046A 1999-02-23 2001-08-20 Gabapentinderivater for forhindring og behandling av visceral smerte NO20014046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99400440A EP1031350A1 (en) 1999-02-23 1999-02-23 Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
PCT/EP2000/001103 WO2000050027A1 (en) 1999-02-23 2000-02-03 Gabapentin derivative for preventing and treating visceral pain

Publications (2)

Publication Number Publication Date
NO20014046D0 true NO20014046D0 (no) 2001-08-20
NO20014046L NO20014046L (no) 2001-08-20

Family

ID=8241887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014046A NO20014046L (no) 1999-02-23 2001-08-20 Gabapentinderivater for forhindring og behandling av visceral smerte

Country Status (14)

Country Link
EP (2) EP1031350A1 (no)
JP (1) JP2002537332A (no)
KR (1) KR20010102314A (no)
CN (1) CN1341018A (no)
AU (1) AU2909800A (no)
BR (1) BR0008323A (no)
CA (1) CA2360528A1 (no)
CZ (1) CZ20012982A3 (no)
EA (1) EA200100721A1 (no)
HK (1) HK1040198A1 (no)
HU (1) HUP0200344A3 (no)
IL (1) IL144872A0 (no)
NO (1) NO20014046L (no)
WO (1) WO2000050027A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
AU2002345664C1 (en) 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
DE10161809A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Arzneimittel enthaltend N,N'-disubstituierte Piperazin-Verbindungen
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
ITMI20022658A1 (it) * 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
JP4308263B2 (ja) 2003-10-14 2009-08-05 ゼノポート，インコーポレイティド γ−アミノ酪酸アナログの結晶形
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
CA2706575C (en) 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
EP2344447B1 (en) 2008-10-08 2016-06-08 Xgene Pharmaceutical Inc Gaba conjugates and methods of use thereof
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
KR101519192B1 (ko) * 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
TWI646111B (zh) 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
CA2903000C (en) 2013-01-28 2021-10-12 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
KR20210013081A (ko) 2018-05-14 2021-02-03 엑스진 파마슈티컬 인크. 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
BR9708200A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Aminoácidos cíclicos substituídos como agentes farmacéuticos
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
IL144872A0 (en) 2002-06-30
EP1031350A1 (en) 2000-08-30
HUP0200344A2 (hu) 2002-05-29
EA200100721A1 (ru) 2002-04-25
WO2000050027A1 (en) 2000-08-31
CN1341018A (zh) 2002-03-20
CA2360528A1 (en) 2000-08-31
CZ20012982A3 (cs) 2002-05-15
HUP0200344A3 (en) 2002-11-28
AU2909800A (en) 2000-09-14
KR20010102314A (ko) 2001-11-15
JP2002537332A (ja) 2002-11-05
EP1154768A1 (en) 2001-11-21
HK1040198A1 (zh) 2002-05-31
NO20014046L (no) 2001-08-20
BR0008323A (pt) 2002-01-29

Similar Documents

Publication Publication Date Title
NO20014046D0 (no) Gabapentinderivater for forhindring og behandling av visceral smerte
NO20015773D0 (no) Forhindring og behandling av amyloidogen sykdom
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
HUP0201205A2 (en) Prevention and treatment of amyloidogenic disease
NO20002784D0 (no) Forhindring og behandling av amyloidogen sykdom
NO20013380D0 (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO985484D0 (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
NO20020784L (no) Medikament for behandling av brudd
NO20026148D0 (no) Medisiner for forhindring og behandling av neurodegenerative sykdommer
EP1173189A4 (en) ASIALOZYTOKINES AND TREATMENT OF LIVER DISEASES
GB9908059D0 (en) Diagnosis and treatment of diseases
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte
IL150208A0 (en) Compound and method for the treatment of pain
NO20013464D0 (no) Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
NO20014476L (no) Behandling av hiatial hernia
EP1165060A4 (en) PROCESSING OF BILARIAL CALCULATIONS
GB9919565D0 (en) Treatment of disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application